174.33
6.32 (3.76%)
前收盘价格 | 168.01 |
收盘价格 | 176.29 |
成交量 | 779,312 |
平均成交量 (3个月) | 574,345 |
市值 | 9,767,134,208 |
预期市盈率 (P/E Forward) | 101.01 |
价格/销量 (P/S) | 14.58 |
股市价格/股市净资产 (P/B) | 4.64 |
52周波幅 | |
利润日期 | 19 Feb 2025 - 24 Feb 2025 |
营业毛利率 | -0.33% |
营业利益率 (TTM) | -2.22% |
稀释每股收益 (EPS TTM) | -0.030 |
季度收入增长率 (YOY) | 9.70% |
季度盈利增长率 (YOY) | -83.40% |
总债务/股东权益 (D/E MRQ) | 37.40% |
流动比率 (MRQ) | 6.65 |
营业现金流 (OCF TTM) | 155.19 M |
杠杆自由现金流 (LFCF TTM) | 120.45 M |
资产报酬率 (ROA TTM) | 0.19% |
股东权益报酬率 (ROE TTM) | -0.10% |
市场趋势
短期 | 中期 | ||
行业 | Medical Instruments & Supplies (US) | 混合的 | 混合的 |
Medical Instruments & Supplies (全球的) | 混合的 | 混合的 | |
股票 | Repligen Corporation | 看涨 | 看跌 |
AIStockmoo 评分
分析师共识 | -1.5 |
内部交易活动 | NA |
价格波动 | 2.0 |
技术平均移动指标 | 0.0 |
技术振荡指标 | 4.0 |
平均 | 1.13 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively. |
|
部门 | Healthcare |
行业 | Medical Instruments & Supplies |
投资方式 | Small Growth |
内部持股比例 | 6.58% |
机构持股比例 | 102.31% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Brown Capital Management Llc | 30 Sep 2024 | 1,119,579 |
Harding Loevner Lp | 30 Sep 2024 | 916,142 |
52周波幅 | ||
目标价格波幅 | ||
高 | 180.00 (HC Wainwright & Co., 3.25%) | 购买 |
中 | 172.50 (-1.05%) | |
低 | 165.00 (Canaccord Genuity, -5.35%) | 保留 |
平均值 | 172.50 (-1.05%) | |
总计 | 1 购买, 1 保留 | |
平均价格@调整类型 | 163.02 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
HC Wainwright & Co. | 23 Jan 2025 | 180.00 (3.25%) | 购买 | 167.90 |
Canaccord Genuity | 17 Dec 2024 | 165.00 (-5.35%) | 保留 | 158.14 |
该时间范围内无数据。
日期 | 类型 | 细节 |
---|---|---|
07 Jan 2025 | 公告 | Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference |
06 Jan 2025 | 公告 | Repligen Launches the CTech™ SoloVPE® PLUS System |
16 Dec 2024 | 公告 | BioLife Solutions Appoints Tony J. Hunt to its Board of Directors |
12 Dec 2024 | 公告 | Repligen Announces Publication of the Company’s 2023 Corporate Sustainability Report |
09 Dec 2024 | 公告 | Repligen Launches Novel AVIPure® dsRNA Resin in OPUS® Pre-packed Columns |
12 Nov 2024 | 公告 | Repligen Reports Third Quarter 2024 Financial Results |
05 Nov 2024 | 公告 | Repligen Corporation to Present at Upcoming Investor Conferences |
31 Oct 2024 | 公告 | Repligen to Report Third Quarter 2024 Financial Results |
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合